Advanced search    

Search: authors:"Hiddo J. L. Heerspink"

7 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

When drug treatments bias genetic studies: Mediation and interaction

curation. Author Contributions Conceptualization: Amand F. Schmidt, Hiddo J. L. Heerspink, Chris Finan, Rolf H. H. Groenwold. Data curation: Amand F. Schmidt, Petra Denig, Chris Finan. Formal analysis ... : Amand F. Schmidt. Investigation: Hiddo J. L. Heerspink, Petra Denig. Methodology: Amand F. Schmidt, Rolf H. H. Groenwold. Supervision: Hiddo J. L. Heerspink, Petra Denig, Chris Finan, Rolf H. H

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease

/creatinine ratio VEGFA Vascular endothelial growth factor A Hiddo J. L. Heerspink and Paul Perco contributed equally to this work. Electronic supplementary material The online version of this article

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors

, 9700 AD Groningen , the Netherlands 1 Ron T. Gansevoort 2 Hiddo J. L. Heerspink 3 Division Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen , PO

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease

Box 30001, 9700 RB Groningen , the Netherlands 1 Hiddo J. L. Heerspink CCL2; Diabetic kidney disease; Inflammation; JAK-STAT; MCP-1 - were assessed in patients with proteinuria more than 30 years ago

Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels

Aldosterone is elevated in chronic kidney disease (CKD) and may be involved in hypertension. Surprisingly, the determinants of the plasma aldosterone concentration (PAC) and its role in hypertension are not well studied in CKD. Therefore, we studied the determinants of aldosterone and its association with blood pressure in CKD patients. We also studied this during renin...

Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease

Center Groningen , P.O. Box 30.001, 9700 RB Groningen , the Netherlands 2 Hiddo J. L. Heerspink 3 Mosaiques Diagnostics GmbH , Hannover , Germany The past decade has resulted in multiple new findings of

Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial

Background Fluid retention is a common adverse event in patients who receive endothelin (ET) receptor antagonist therapy, including the highly selective ETA receptor antagonist, atrasentan. Objective We performed longitudinal assessments of thoracic bioimpedance in patients with type 2 diabetes mellitus and nephropathy to determine whether a decrease in bioimpedance accurately...